Tradestie Institutional Equity Comparison Engine

VOR vs CGEM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

VOR Overall Edge

VOR Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vor Biopharma Inc. Common Stock (VOR) driven by superior Momentum & Technical, Options & Structure while CGEM counters with relative strength in Valuation, Growth & Margin. Fundamentally, VOR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CGEM at 6.7x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VOR sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against CGEM sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEM
VOR N/M vs CGEM 6.7x Fwd P/E
Growth & Margin Winner CGEM
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner VOR
1Y +97.5% vs +16.7% ยท 52W Pos 65% vs 11%
Options & Structure Winner VOR
CONSOLIDATION (6th %ile IV) vs UNCLASSIFIED (9th %ile IV)
VOR NASDAQ
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.26
-0.82% 1D
Market Cap $1.2B
1M Return +6.82%
1Y Return +97.54%
Forward P/E N/M
Unified AI Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
CGEM NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.65
-6.13% 1D
Market Cap $653.8M
1M Return -25.37%
1Y Return +16.69%
Forward P/E 6.7x
Unified AI Score
41.0 / 100 SELL
Tech 25.0 Fund 51.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VOR +97.54% CGEM +16.69% Spread: +80.85 pp (VOR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
VOR TTM Op. Margin: 0.0% CGEM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs CGEM. Trailing 12-month operating profitability (VOR 0.0% vs CGEM 0.0%) and valuation multiples (VOR N/M vs CGEM 6.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VOR (5) vs CGEM (2)
Institutional Metric VOR CGEM Criterion Row Winner
Market Capitalization Scale $1.2B $653.8M Larger Scale VOR
Trailing P/E Ratio Valuation 0.1x 6.7x Lower Multiple VOR
Forward P/E Ratio Valuation N/M 6.7x Lower Multiple CGEM
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -125.4% -50.3% Higher ROE CGEM
52-Week Range Position Momentum 65% ($6โ€“$26) 11% ($8โ€“$23) Stronger Trend VOR
Beta / 30D Volatility Risk Regime 1.91ฮฒ ยท 61% Vol 1.58ฮฒ ยท 105% Vol Lower Realized Risk VOR
Unified Institutional Score Composite Signal 57.8 / 100 (HOLD) 41.0 / 100 (SELL) Higher Composite VOR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VOR vs CGEM Buy Guide
VOR CONSOLIDATION
52d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live VOR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGEM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live CGEM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VOR nor CGEM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.